NCT07448194

A Phase Ia Clinical Trial of HW241045

A Phase Ia Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of HW241045 Tablets Following a Single Dose in Healthy Subjects: A Single-center, Randomized, Double-blind, Placebo-controlled Study

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (estimated)
• Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a Phase Ia, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetic (PK) of HW241045 in healthy subjects following a single ascending dose.

Conditions

• Healthy Volunteers
• IPF

Interventions

Type	Name	Description
DRUG	HW241045	Dose 1 to Dose 7
DRUG	Placebo	Dose 1 to Dose 7

Timeline

• Start date: 2025-11-24
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2026-03-04
• Last updated: 2026-03-04

Locations

1 site across 1 country: China